Antithymocyte Globulin in Reduced-Intensity Conditioning Allografting: Is the Benefit Simply in the Eyes of the Transplanter?  by Hamadani, Mehdi
M. Hamadani / Biol Blood Marrow Transplant 20 (2014) 291e294292tested to illuminate mechanisms underlying the inﬂamma-
tion, dysregulated repair, and collagen deposition character-
istic of OLD and RLD [7,8]. Furthermore, new strategies,
including the administration of etanercept (a soluble TNF-
aebinding protein) and combination therapy with ﬂutica-
sone, azithromycin, and montelukast (FAM), have shown
promise [9] and are currently undergoing further testing [10].
More remains to be done, however. For starters, consis-
tent approaches to the monitoring of pulmonary function
(including the utility of expanded use of hand-held spirom-
etry) after allogeneic HCT, diagnostic workup (including the
roles of bronchoscopy and computed tomography) of
affected patients, and classiﬁcation of lung dysfunction
(particularly RLD) once identiﬁed, along with clinical
guidelines for the initiation of inhaled or systemic therapy,
are lacking and need to be established. Furthermore, ad-
vances in radiographic imaging that may allow earlier
detection of progressive parenchymal or small airway
inﬂammation [11] and overcome limitations of available
diagnostic tools should be explored in allogeneic HCT re-
cipients with suspected OLD or RLD. Thus, steps to address
“boring” but critical knowledge gaps in standard of practice
can be complemented by cutting-edge technology and pro-
vide a platform to determine whether early detection of
pulmonary dysfunction will enhance the success of timely
intervention with novel immunomodulatory therapy. The
addition of patient sample procurement (ie, bronchoalveolar
lavage ﬂuid, plasma, and stool) at deﬁned time points in such
an endeavor will allow for clinical biomarker discovery and
exploration of nonconventional infectious etiologies of OLD
and RLD using next-generation sequencing techniques as
described for other HCT complications [12,13].
Despite the tremendous advances in transplantation
biology and clinical care over the last several decades, cGVHD
and pulmonary toxicity remain the scourges of allogeneic
HCT recipients, negatively impacting quality of life and
limiting successful outcomes. It is hoped that future ex-
ploration using animal models and the development of
innovative and comprehensive clinical trials will allow
investigators to better deﬁne and exploit the window
of opportunity for patients with late-onset pulmonaryFinancial Disclosure: None relevant to the article.
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Accepted 28 December 2013In the modern era, graft-versus-host disease (GVHD) and
associated nonrelapse mortality (NRM) continue to plague
allogeneic hematopoietic cell transplantation (allo-HCT)
outcomes. A variety of strategies has been developed to
preventGVHDafter allo-HCT, includingex vivo or in vivoTcell
depletion, pharmacological inhibition of Tcell proliferation or
trafﬁcking, monoclonal antibodies, and immune-modulation
(to name a few), but the best prophylactic modality remains
controversial.
In vivo T cell depletionwith antithymocyte globulin (ATG)
is commonly performedbyadministering 1 of 3 commercially
M. Hamadani / Biol Blood Marrow Transplant 20 (2014) 291e294 293available products (Thymoglobulin [Genzyme Corporation,
Cambridge, MA], ATGAM [Pﬁzer, New York, NY], or ATG-Fre-
senius [Fresenius Biotech GmbH, Germany]) [1]. ATG pre-
vents GVHD not only through in vivo donor effector T cell
depletion but also via pleiotropic effects on the immune
system, including depletion and modulation of antigen-
presenting cells, modulation of cell surface molecules that
mediate leukocyte/endothelium interactions, and induction
of regulatory T cells [2,3]. The efﬁcacy of ATG in preventing
GVHD is intricately dependent not only on the dose and type
of ATG preparation used and on the timing of ATG adminis-
tration, but also on transplant characteristics including the
type of donor (sibling versus unrelated) and graft (bone
marrow versus peripheral blood) source used, degree of HLA
matching, and intensity of conditioning regimens. The com-
plex interplay of so many confounding variables affecting
the efﬁcacy of ATG makes interpreting data of clinical
trials evaluating the role of ATG as GVHD prophylaxis
problematic.
A meta-analysis [4] of seven randomized studies [5-8]
using mostly myeloablative conditioning regimens and an
invariably heterogeneous patient population (in terms of
ATG preparation, disease type, donor and stem cell source,
etc.), showed reduced rates of grades III to IV acute GVHD in
patients receiving ATG, but without any reduction in the
rates of grades I to II acute GVHD, NRM, or an overall survival
beneﬁt. Although the above meta-analysis [4] and some
randomized trials [5] suggest that in the setting of unrelated
donor myeloablative transplantation, ATG can mitigate the
risk of GVHDwithout negatively affecting survival outcomes,
extrapolating these data to reduced-intensity conditioning
(RIC) allo-HCT, without supporting randomized data, war-
rants careful reappraisal.
In this issue of Biology of Blood and Marrow Trans-
plantation, Devillier et al. [9] report retrospective outcomes of
209 patients undergoing RIC allo-HCT with ﬂudarabine,
busulfan, and thymoglobulin. Sixty percent of included pa-
tients underwent matched sibling HCT. Using a total thy-
moglobulin dose of 5 mg/kg, the authors report grades III to
IV acute and extensive chronic GVHD rates of 9% and 22%,
respectively. Four-year NRM, relapse rate, and overall survival
rates were 22%, 36%, and 54%, respectively. Infections notably
accounted for most NRM (34 of 43 events). This study, in line
with previously published uncontrolled reports, suggests
acceptable allo-HCToutcomes after ATG-based RIC. However,
key questions remain unanswered regarding the superiority
of this approach (compared with other non-ATGecontaining
options), optimal dose intensity of thymoglobulin, suitable
patient population, and the impact of this approach on post-
transplant disease control, infectious complications, immune
reconstitution, and survival outcomes.
The lack of randomized trials demonstrating beneﬁt of
ATG as GVHD prophylaxis in RIC allo-HCT cannot be over-
emphasized. Soiffer et al. [10] examined the impact of ATG
use on outcomes of RIC allo-HCT in a Center for International
Blood and Marrow Transplant Research (CIBMTR) analysis.
Compared with patients receiving a T cellereplete graft, ATG
use in this important study did not reduce the rates of grades
II to IV (40% versus 38%) and III to IV acute GVHD (22% versus
21%). This CIBMTR analysis [10], the report by Devillier et al.
[9], and others have shown low rates of chronic GVHD with
the inclusion of ATG in RIC. It is important to note, however,
that these studies predominantly used peripheral blood
grafts. Whether the same degree of beneﬁt could be derived
by preferentially using bone marrow as an unrelated donorallograft source, with its associated reduced risk of chronic
GVHD [11], is not clear.
The use of ATG has not been shown to be associated with
a higher risk of disease relapse in patients undergoing
myeloablative allo-HCT [4], a situationwhere the intensity of
conditioning contributes signiﬁcantly toward post-HCT dis-
ease control. Whether ATG is detrimental for disease control
in RIC allografts, that primarily relying on conditioning in-
tensity depends more heavily on graft-versus-malignancy
effects mediated by donor T cells (a subset likely impacted
by in vivo T cell depletion), merits careful consideration. In
the CIBMTR analysis described above [4], increased rates of
relapse were observed with ATG use compared with unma-
nipulated grafts (51% versus 38%, respectively), which in turn
resulted in inferior survival outcomes post-RIC allo-HCT.
Despite the retrospective nature of the analysis and the
biases inherent in registry analyses, this study cautions
against the routine use of ATG in RIC regimens. An increased
risk of relapse is a particularly important consideration for
patients with high or very-high disease risk index, as illus-
trated by higher relapse rates of such patients in the study by
Devillier et al. [9].
The optimal dose intensity of thymoglobulin in RIC allo-
HCT is poorly deﬁned. Mohty et al. [12], in a series of pa-
tients undergoing (matched sibling) allo-HCT, observed a
signiﬁcant increase in rates of acute and chronic GVHD
when thymoglobulin dose was reduced from 7.5 mg/kg to
2.5 mg/kg. We have previously shown that reduction of
thymoglobulin dose from 7.5 mg/kg to 6 mg/kg in RIC
unrelated donor HCT maintains GVHD control and may
favorably affect NRM. Devillier and colleagues should be
commended for their continued efforts in further deﬁning
the optimal dose intensity of thymoglobulin (ie,w5 mg/kg)
in RIC allografts [8,13,14]. Collectively, these data suggest
that if incorporated in RIC regimens, thymoglobulin doses
should not exceed the 5- to 6-mg/kg (total dose) range.
These assumptions obviously do not apply to nonthymo-
globulin ATG preparations. When compared with higher
doses (7.5 mg/kg), reduced thymoglobulin doses do
appear to be associated with a reduced risk of infectious
complications. It is important to remember, however, that
these risks are by no means insigniﬁcant. Patients receiving
thymoglobulin with RIC allo-HCT remain susceptible to
frequent viral reactivations, fungal and bacterial infections,
and post-transplant lymphoproliferative disorders, all of
which require signiﬁcant post-transplant resource utiliza-
tion for monitoring and treatment. This fact needs to be
considered when applying in vivo T cell depletion, espe-
cially in matched sibling allografts, where risk of GVHD is
relatively lower.
Prospective trials comparing ATG-based prophylaxis
against novel GVHD preventive strategies [15-17] for pa-
tients undergoing RIC (from uniform donor and stem cell
sources) are unlikely to be performed. In the absence of such
high-quality randomized data, the decision to include ATG
in RIC allo-HCT will be directed largely by transplant center
and treating physician preference. Although proponents of
this approach cite low rates of acute and chronic GVHD and
possibly less frequent infectious complications with lower
ATG doses as reasons to include in vivo T cell depletion
in RIC programs, opponents will continue to highlight
compromised disease control, signiﬁcant infectious com-
plications, delayed immune reconstitution, and the lack of
any demonstrable overall survival beneﬁt or quality-of-life
improvement with ATG use as arguments against this
M. Hamadani / Biol Blood Marrow Transplant 20 (2014) 291e294294strategy. It appears that, like beauty, the beneﬁts of ATG lie
largely in the eye of the beholder (or transplanter).REFERENCES
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